Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228567 | 1.00 | CYP2D6 (0.48) | CYP2D6CYP2C19USP2TSHRLMNA | |
| SCHEMBL3229211 | 0.86 | LMNA (0.50) | CYP2D6CYP2C19TSHRLMNA | |
| SCHEMBL3229217 | 0.86 | LMNA (0.50) | CYP2D6CYP2C19TSHRLMNA | |
| SCHEMBL1965030 | 0.83 | CYP2D6 (0.41) | CYP2D6CYP2C19 | |
| SCHEMBL1967425 | 0.83 | CYP2D6 (0.41) | CYP2D6CYP2C19 | |
| SCHEMBL3232227 | 0.83 | CYP2D6 (0.54) | CYP2D6CYP2C19USP2TSHR | |
| SCHEMBL3232233 | 0.83 | CYP2D6 (0.54) | CYP2D6CYP2C19USP2TSHR | |
| SCHEMBL1964938 | 0.80 | CYP2D6 (0.38) | CYP2D6CYP2C19LMNA | |
| SCHEMBL1965299 | 0.80 | CYP2D6 (0.38) | CYP2D6CYP2C19LMNA | |
| SCHEMBL23795382 | 0.78 | CYP2D6 (0.54) | CYP2D6CYP2C19USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987251-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8575145-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2334677-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | CYP2D6 1731/4885CYP2C19 2350/4885USP2 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.